Sangamo Therapeutics approaches its May 7 earnings release with short sellers firmly in control of the tape — and a stock that has lost 41% in a month to trade at $0.18.
Short interest tells the dominant story into this print. At 9.4% of free float — up 15% in the past week — bears have been adding exposure aggressively, not covering. The week-on-week jump follows the stock's late-March earnings shock, when the stock fell 23% in a single session. Official FINRA data corroborates the pressure: 42.9 million shares short, with 6.78 days to cover. Despite the elevated SI, borrow availability remains generous. Cost to borrow is running at just 0.64% APR — near its lows for the period — suggesting there is no meaningful friction preventing further short positioning. The lending market is loose, not tight.
Options positioning does not augment the bearish read. The put/call ratio has edged marginally above its 20-day average at 0.33, a fraction of a standard deviation from normal, and far below the 52-week high of 1.13. That low PCR signals options traders are leaning toward calls — an asymmetric bet on a positive catalyst — rather than hedging downside into the print.
The fundamental debate hinges on the FDA-agreed path for isa-vec, Sangamo's gene therapy targeting Fabry disease. The bull case rests on an Accelerated Approval BLA filing framework, supported by up to 4.5 years of Phase 1/2 STAAR data showing sustained renal function improvement and stable cardiac metrics. HC Wainwright has maintained a Buy with a $10 target throughout the past year. The bear case is harder to dismiss at the current price: the company carries significant operating losses, a pipeline dependent on partnership funding, and a balance sheet under strain. Barclays downgraded to Equal-Weight in November 2025 and cut its target to $1.00. The mean analyst price target of $3.75 is roughly 20x the current stock price — a gap that almost certainly reflects stale or pre-restructuring estimates rather than current consensus, and should be treated with caution. RBC holds Sector Perform with a $2 target.
Insider activity adds a footnote worth noting. Across late February and April, multiple executives — including CEO Alexander Macrae — recorded small sells, primarily below $0.50. Net insider value sold over 90 days was approximately $235,000. These are modest in dollar terms, but no insider has been a buyer, and the CEO has been a consistent seller as the stock has declined.
The May 7 print is ultimately a test of whether Sangamo can articulate a credible path to a BLA filing for isa-vec — and whether any partnership progress can offset the cash-burn narrative that has dominated the stock's collapse to penny-territory.
See the live data behind this article on ORTEX.
Open SGMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
